Hodges Capital Management Inc. purchased a new position in shares of Pfizer Inc. (NYSE:PFE) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 5,649 shares of the biopharmaceutical company’s stock, valued at approximately $202,000.
Several other large investors have also recently made changes to their positions in PFE. First Command Bank boosted its stake in shares of Pfizer by 131.5% during the 2nd quarter. First Command Bank now owns 23,934 shares of the biopharmaceutical company’s stock worth $804,000 after acquiring an additional 13,596 shares in the last quarter. Stock Yards Bank & Trust Co. raised its position in shares of Pfizer by 0.7% during the 2nd quarter. Stock Yards Bank & Trust Co. now owns 123,800 shares of the biopharmaceutical company’s stock worth $4,159,000 after purchasing an additional 832 shares during the last quarter. Factory Mutual Insurance Co. raised its position in shares of Pfizer by 2.1% during the 2nd quarter. Factory Mutual Insurance Co. now owns 2,935,897 shares of the biopharmaceutical company’s stock worth $98,617,000 after purchasing an additional 60,000 shares during the last quarter. Prentiss Smith & Co. Inc. raised its position in shares of Pfizer by 4.0% during the 2nd quarter. Prentiss Smith & Co. Inc. now owns 15,548 shares of the biopharmaceutical company’s stock worth $522,000 after purchasing an additional 600 shares during the last quarter. Finally, Capstone Asset Management Co. raised its position in shares of Pfizer by 79.4% during the 2nd quarter. Capstone Asset Management Co. now owns 342,493 shares of the biopharmaceutical company’s stock worth $11,504,000 after purchasing an additional 151,626 shares during the last quarter. 69.75% of the stock is currently owned by institutional investors and hedge funds.
In other news, EVP Rady A. Johnson sold 8,000 shares of the business’s stock in a transaction on Friday, December 15th. The shares were sold at an average price of $37.07, for a total transaction of $296,560.00. Following the completion of the sale, the executive vice president now directly owns 46,963 shares of the company’s stock, valued at approximately $1,740,918.41. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Alexander R. Mackenzie sold 14,700 shares of the business’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $35.30, for a total transaction of $518,910.00. Following the sale, the insider now directly owns 117,432 shares of the company’s stock, valued at $4,145,349.60. The disclosure for this sale can be found here. Insiders sold a total of 29,450 shares of company stock valued at $1,065,220 over the last quarter. 0.06% of the stock is currently owned by insiders.
Several research analysts recently issued reports on the company. Zacks Investment Research upgraded Pfizer from a “hold” rating to a “buy” rating and set a $41.00 price objective for the company in a research report on Wednesday. Morgan Stanley set a $41.00 price objective on Pfizer and gave the stock a “buy” rating in a research report on Friday, January 5th. BMO Capital Markets set a $39.00 price objective on Pfizer and gave the stock a “buy” rating in a research report on Monday, January 8th. Vetr downgraded Pfizer from a “buy” rating to a “hold” rating and set a $37.98 price objective for the company. in a research report on Monday. Finally, Jefferies Group set a $40.00 price objective on Pfizer and gave the stock a “neutral” rating in a research report on Tuesday. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and thirteen have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $38.94.
Pfizer Inc. (NYSE PFE) opened at $37.18 on Thursday. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56. The firm has a market capitalization of $218,161.88, a price-to-earnings ratio of 22.95, a price-to-earnings-growth ratio of 2.45 and a beta of 1.01. Pfizer Inc. has a twelve month low of $30.90 and a twelve month high of $37.37.
Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.02. The company had revenue of $13.17 billion during the quarter, compared to the consensus estimate of $13.17 billion. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. Pfizer’s revenue was up .9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.61 EPS. equities research analysts anticipate that Pfizer Inc. will post 2.59 earnings per share for the current fiscal year.
Pfizer announced that its Board of Directors has initiated a stock buyback plan on Monday, December 18th that authorizes the company to buyback $10.00 billion in shares. This buyback authorization authorizes the biopharmaceutical company to purchase shares of its stock through open market purchases. Shares buyback plans are often a sign that the company’s leadership believes its shares are undervalued.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, February 2nd will be issued a $0.34 dividend. The ex-dividend date is Thursday, February 1st. This is an increase from Pfizer’s previous quarterly dividend of $0.32. This represents a $1.36 annualized dividend and a yield of 3.66%. Pfizer’s payout ratio is 79.01%.
COPYRIGHT VIOLATION NOTICE: “Hodges Capital Management Inc. Purchases Shares of 5,649 Pfizer Inc. (PFE)” was originally published by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://transcriptdaily.com/2018/01/18/hodges-capital-management-inc-purchases-shares-of-5649-pfizer-inc-pfe.html.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.